Meeting highlights from the PRAC 2326 October 2023 GLP-1 receptor agonists: available evidence not supporting link with thyroid cancer
Disclosed by Eli Lilly investigators in 2022 under the development code LY3437943, retatrutide builds conceptually on the dual-incretin foundation established by tirzepatide while extending receptor engagement to include the glucagon receptor, a pharmacological pathway that earlier incretin research had largely avoided due to concerns about hyperglycemia and lipolysis
These medications are designed to resist this breakdown, allowing them to work for hours or even an entire week
This is especially relevant for patients who: Want to combine a medical weight loss program with aesthetic treatments (body contouring, skin tightening, etc.) Have already spent down their HSA or FSA balance Are interested in services like the Verj laser treatment for body contouring alongside their weight loss plan Financing allows you to split payments over time without waiting until youve saved enough cash
Pereira-Miranda, E., Costa, P
